1. Home
  2. CINGW vs JZXN Comparison

CINGW vs JZXN Comparison

Compare CINGW & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • JZXN
  • Stock Information
  • Founded
  • CINGW N/A
  • JZXN 2019
  • Country
  • CINGW United States
  • JZXN China
  • Employees
  • CINGW 13
  • JZXN N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • JZXN Retail-Auto Dealers and Gas Stations
  • Sector
  • CINGW Health Care
  • JZXN Consumer Discretionary
  • Exchange
  • CINGW Nasdaq
  • JZXN Nasdaq
  • Market Cap
  • CINGW N/A
  • JZXN N/A
  • IPO Year
  • CINGW 2021
  • JZXN 2021
  • Fundamental
  • Price
  • CINGW $0.03
  • JZXN $2.97
  • Analyst Decision
  • CINGW
  • JZXN
  • Analyst Count
  • CINGW 0
  • JZXN 0
  • Target Price
  • CINGW N/A
  • JZXN N/A
  • AVG Volume (30 Days)
  • CINGW N/A
  • JZXN 341.3K
  • Earning Date
  • CINGW N/A
  • JZXN 05-19-2025
  • Dividend Yield
  • CINGW N/A
  • JZXN N/A
  • EPS Growth
  • CINGW N/A
  • JZXN N/A
  • EPS
  • CINGW N/A
  • JZXN N/A
  • Revenue
  • CINGW N/A
  • JZXN $1,400,139.00
  • Revenue This Year
  • CINGW N/A
  • JZXN N/A
  • Revenue Next Year
  • CINGW N/A
  • JZXN N/A
  • P/E Ratio
  • CINGW N/A
  • JZXN N/A
  • Revenue Growth
  • CINGW N/A
  • JZXN N/A
  • 52 Week Low
  • CINGW N/A
  • JZXN $1.00
  • 52 Week High
  • CINGW N/A
  • JZXN $7.82
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • JZXN 39.59
  • Support Level
  • CINGW N/A
  • JZXN $1.54
  • Resistance Level
  • CINGW N/A
  • JZXN $7.82
  • Average True Range (ATR)
  • CINGW 0.00
  • JZXN 1.31
  • MACD
  • CINGW 0.00
  • JZXN -0.20
  • Stochastic Oscillator
  • CINGW 0.00
  • JZXN 22.77

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: